Kornimate/medical-research-clean huggingface dataset:
oculomotor training improves reading eye movement

Conditions: Ocular Motility Disorders

Summary: children with reading eye movement problems were recruited for this study. the treatment group was provided with oculomotor training for 8 weeks, the control group was given placebo exercises.

purpose of study reading is one of the integral elements for learning and poor readers were reported to have less efficient reading eye movements. they were typically characterized by having higher number in fixation and regression, reduced reading speed and perceptual span. the purpose of this study was to investigate if vision therapy which limited to training of oculomotor skills can improve reading eye movement. methodology this was a randomized, prospective study. 30 subjects aged from 8-9 years of age with reading difficulties and reading eye movement problems were recruited. they all have normal intelligence and ocular health, but failed to meet the taylor reading eye movement norms when tested with the visagraph iii. the subjects were randomly assigned into either the treatment group (15) or the control group (15). the treatment group had to go through a course of oculomotor vision therapy and the control group was given placebo exercises. vision therapy for the treatment group involved 8 weeks of training (office training - 3 times a week, 30 min per session; home training - 4 times a week, 30 min per session). office training involved the use of vis-flex (visual flexibility trainer - an electronic device with l.e.d. lights which can display various flashing patterns at variable speeds). home training involved several saccadic eye movement exercises. subjects and parents were also asked to grade the reading symptoms checklist before and after the training.

Eligibility criteria:
inclusion criteria: * reported by teachers or parents to have reading difficulties and failed to meet the taylor reading eye movement norms when tested with the visagraph iii (below age norm for both fixation and regression number). * studying in mainstream primary schools (8-9 years of age) * with normal near visual acuities for both eyes (with or without spectacles) * hyperopia below +4.00 d * myopia below -4.00 d * astigmatism below -2.00 d * anisometropia less than 2.0 d difference between the two eyes * near heterophoria within 0-4 exophoria * vertical heterophoria less than 1 prism dioptre * monocular amplitude of accommodation over 10 d in both eyes * with parents who were willing to perform vision therapy exercises for the children at home on a regular basis * both genders were acceptable as eden et al (1994) stated that gender had no effect on oculomotor skills exclusion criteria: * with strabismus * presence of eye diseases * history of dyslexia (learning disability) or developmental delay

Keywords: reading eye movement
safety and efficacy of switching from a stimulant medication to atomoxetine in children and adolescents with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to assess changes in adhd symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.


Eligibility criteria:
inclusion criteria: * patients must be at least 6 years of age and not yet be 18 years of age at the completion of visit 6 * patients must meet dsm-iv diagnostic criteria for adhd (any subtype) * patients must have laboratory results showing no significant abnormalities (significant would include laboratory deviations requiring acute medical intervention or further medical evaluation) * patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator's judgment, to achieve a score of greater than or equal to 70 on a iq test) * patients must be able to swallow capsules exclusion criteria: * patients who weigh less than 22 kg or more than 70 kg at study entry * patients who have a history of bipolar i or bipolar ii disorder, psychosis, or a pervasive developmental disorder * patients with a history of any seizure disorder (other than febrile seizures) or prior eeg abnormalities related to epilepsy, or patients who have taken (or are currently taking) anticonvulsants for seizure control * patients with a history of severe allergies to more than one class of medication, or multiple adverse drug reactions * patients who have glaucoma
shensongyangxin capsule in the treatment of sinus bradycardia with premature ventricular contractions

Conditions: Premature Ventricular Contraction

Summary: the purpose of this study is to assess the effects of chinese medicine shansong yangxin capsule for sinus bradycardia complicated with ventricular premature beats.

premature ventricular contractions is one of the most common symptomatic arrhythmia. antiarrhythmia drugs for premature ventricular contractions, such as beta-blockers and sodium channel blockers, can cause bradycardia. for sinus bradycardia patients complicated with premature ventricular contractions, it's hard for doctors to make decision. the purpose of the study is to assess the effects of chinese medicine shansong yangxin capsule for sinus bradycardia complicated with ventricular premature beats, which based on the numbers of premature ventricular contractions and average hear rate in 24-hour ambulatory electrocardiogram (ecg) after 8 weeks treatment as the primary endpoint of the study. secondary endpoints are evaluation of the shensong yangxin capsule on quality of life. this study is a randomized, double-blind, placebo controlled, multi-center trial. sinus bradycardia patients(average heart rate 45-59 beat per minute) associated with premature ventricular contractions (pvc number \>10000 / 24h), are involved in the study. patients are randomly assigned into shensong yangxin capsule group or placebo group, with the capsule administration of 4 granules t.i.d.for 8 weeks. 24-hour ambulatory ecg, are observed at baseline,4 weeks and 8 weeks after the intervention. the primary outcomes are the numbers of premature ventricular contractions and average heat rate in 24-hour ambulatory ecg, and the secondary outcomes is minnesota living with heart failure questionnaire (mlhfq).

Eligibility criteria:
inclusion criteria: * 18 years to 70 years old * documented sinus bradycardia with average heart rate at 45-59 by 24hours ambulatory ekg * ventricular premature beats: \>1000 beats/24 hours exclusion criteria: * younger than 18 years or older than 75 years * symptomatic sinus arrest \>3 seconds or high degree atrioventricular block indicated for pacemaker * subject suffered from acute coronary syndrome in last three months (acute myocardial infarction of st segment elevation and non st segment elevation, unstable angina * to be complicated with persistent atrial fibrillation, or paroxysmal atrial fibrillation \>5% during 24hrs ambulatory ekg or acute myocarditis * to be complicated with ventricular fibrillation, torsion type ventricular heartbeat rate, sustained ventricular tachycardia, or non sustained ventricular tachycardia with rapid ventricular rate and hemodynamic disorders * sinus heart rate less than 45 beats/minutes and needs to receive the pacemaker or has received pacemaker, or with icd,crtp/d

Keywords: sinus bradycardia ventricular premature contraction
benzocaine gel toothache dose-response study

Conditions: Toothache

Summary: to evaluate the efficacy and safety of benzocaine gel products for the relief of toothache and to assess the subject's compliance with proposed label directions.


Eligibility criteria:
inclusion criteria: * males or females at least 12 years of age. * presence of spontaneous toothache pain in only one permanent tooth. toothache pain is due only to an open tooth cavity and only as a result of dental caries, loss of a restoration or tooth fracture. * to qualify for the study, the subject must have a rating of at least moderate pain on the dental pain scale (dps) and a score of at least 50 mm on the visual analog scale. to be included in the moderate pain stratum, the subjects must have a rating of moderate pain in the dps and to be included in the severe pain stratum the subjects must have a rating of severe pain in the dps. * females who are neither pregnant, as verified by a urine-based pregnancy test, nor breast-feeding. * female subjects of childbearing potential and those who are post-menopausal for less than 2 years must be using a medically approved method of contraception (i.e., oral, transdermal or implanted contraceptive devices, intrauterine device, diaphragm, condom, abstinence, or surgical sterility). * subjects must be reliable, cooperative and of adequate intelligence to read and understand the rating scales and other study instructions. * subjects must be able to read, comprehend, and sign the consent form. minors will provide assent to study participation if age appropriate. parent/legal guardian must be able to read, comprehend, and sign the informed consent form. exclusion criteria: * presence of spontaneous toothache pain in a primary tooth. presence of spontaneous toothache pain in more than one tooth. presence of an open tooth cavity in a tooth adjacent to the painful tooth with the open tooth cavity. * presence of concomitant oral pain due to any other condition such as: soft-tissue lesions (e.g., aphthous or traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis); or multiple hard-tissue (e.g., carious) lesions; pain due to other surgical procedures, injuries or dental surface sensitivity. * presence of a periodontal abscess as diagnosed from an x-ray or clinical examination of the painful tooth. * presence of glucose-6-phosphate dehydrogenase (g6pd) deficiency. * history of acute or chronic hemolytic anemia. * history of sensitivity or allergy to benzocaine or other local anesthetic agents. * use of any short-acting oral or topical analgesic/ anesthetic product within 2 hours of enrollment or any long-acting rx or otc analgesic product within 4 hours of enrollment. * use of an investigational drug or participation in an investigational study within the past 30 days. * previous participation in this study. * member or a relative of the study site staff or sponsor directly involved in the study.
national retrospective study of duodenal trauma

Conditions: Duodenal Diverticulization; Pyloric Exclusion; Gastrojejunostomy; Retrograde Duodenostomy; Distal Feeding Tube; Resection and Whipple Procedures; Primary Repairs

Summary: duodenal injuries remain rare among abdominal trauma, concerning less than 5 % of cases. however, due to its central location, it is most commonly associated with multiple organs lesions, with the main three organs being the liver, the colon and the pancreas. additionally, the penetrating mechanism is four times more common than blunt trauma and the most common duodenal site of injury is the second portion (36 %), the least being the first duodenum (13 %). these particularities generate a high morbidity, ranging from 22 to 27.1 %, and a mortality still as high as 5.3 to 30 % today. when facing it, surgeons are usually challenged in their strategy. indeed, when surgery is required, different options can be chosen depending on the grade of the lesion and the involvement of the papilla and/or other organs. primary repairs, duodenal diverticulization, pyloric exclusion, gastrojejunostomy, retrograde duodenostomy, distal feeding tube, or even resection and whipple procedures, have all been described. since the classification of the american association for the surgery of trauma (aast), most studies stratified their management as such: drainage only or primary repair for grade 1 and 2, jejunostomy and/or pyloric exclusion for grade 3, whipple for grade 4 or 5. however, reviews of the literature aren't clear if this decisional tree is in correlation with lower morbidities, and often different procedures have been reported for the same grade. the escalation of technical exclusions among severe grades became controversial. as an example, pyloric exclusion has been criticized in its preventive role of protecting the suture, being useless at least, or even worse at times. thus, in the recent years, the management has been focused towards minimization. indeed, in the retrospective review of the pan-american trauma society primary repair alone was performed in 80 % of cases, all grades comprised. although mortality was high, duodenal suture line leak was statistically lower among survivors over every grade. to clear the situation, prospective studies are difficult if not impossible in such context. thus, the investigators propose this national benchmark, to retrospectively review in france the management of duodenal trauma, depending on the grade, and its associated morbidity.


Eligibility criteria:
inclusion criteria: * patients with duodenal trauma, * older than 18 years old. exclusion criteria: * pregnancy * previous duodenal surgery. * associated surrounding organs trauma, was not an exclusion criterion, but duodenal trauma must have been one of the main injuries.
thromboablation in acute myocardial infarction

Conditions: ST Elevation Acute Myocardial Infarction

Summary: 1. assess whether excimer laser coronary atherectomy (elca) before direct infarct-related artery (ira) stenting results in improved reperfusion success in patients presenting with acute st wave elevation myocardial infarction (stemi) and angiographically evident thrombus. 2. validate an elca technique for the treatment of stemi, at high-volume centers experienced in the treatment of acute myocardial infarction (ami).


Eligibility criteria:
inclusion criteria: electrocardiographic inclusion criteria: (baseline 12-lead ecg recorded at 25 mm/second upon arrival at investigational center) * stemi within 12 hours of symptom onset, with ≥ 2 mm st segment elevation in two or more leads and minimum ≥ 3 mm st segment elevation in one lead. angiographic inclusion criteria after crossing with guidewire: * ira is a native coronary artery; and, * reference vessel diameter 2.5 - 4.0 mm; and, * timi 0 or 1 flow with any timi thrombus grade; or, * timi 2 or 3 flow with timi thrombus grade 3 or greater exclusion criteria: * patient unwilling or unable to give informed consent * previous mi in the distribution of the current ira * previous cabg * contraindications to pci * allergy(s) to intended study medications * contraindicated for stent implantation * active bleeding or coagulopathy * patient in cardiogenic shock (\<90mmhg sbp and/or requiring iabp or vasopressors) * known left ventricular ejection fraction (ef) \<30% * fibrinolytic administered before pci * renal insufficiency (creatinine \>2.0mg/dl) * current vitamin k antagonist therapy or known inr \>1.5 * known thrombocytopenia - platelets \<100,000 cell count * patient has left bundle branch block (lbbb) or pacemaker rhythm * known history of hemorrhagic stroke (cva or tia) \<2 years before screening * known or suspected pregnancy * current cancer disease * comorbidity where survival is anticipated to be \<1 year. * no future patient cooperation expected * patient is participating in another clinical study * patient \<18 years of age

Keywords: stemi laser thrombus thrombectomy
clinical success of short dental implants alone and standard dental implants combined with osteotome sinus floor elevation in posterior maxillae

Conditions: Jaw, Edentulous, Partially

Summary: the aim of this study is to determine the clinical success of short implants (6mm) alone and standard implants (10mm) combined with sinus floor elevation in atrophic maxilla.

implant treatment in posterior maxilla is commonly faced with great challenges due to the limited residual bone height and poor bone quality. efforts have been made to allow successful implant treatment in atrophic posterior maxillae.osteotome sinus floor elevation (osfe) has been proven to be a predictable surgical procedure to vertically increase the bone volume in atrophic maxilla.on the other hand, short implants (intra-bony length of 8mm or less) are being increasingly used in extremely resorbed maxilla to avoid additional surgical trauma and expense.however, still limited randomized controlled trials have compared the clinical success of short implants and standard implants combined with osfe. this study is designed as a prospective randomized controlled clinical study. we plan to enroll 180 patients in need of dental implant treatment in posterior maxilla. all patients will sign the informed consent form before treatment. the study is approval by the ethics committee of shanghai ninth people hospital, china. the clinical component of the study will be initiated in may 2015 at the department of oral and maxillofacial implantology, shanghai ninth people hospital, shanghai jiao-tong university, china. a block randomization sequence will be used to assign eligible patients to three groups: group 1: short implants (6mm) alone; group 2: standard implants (10mm) combined with osfe. the assignment will be concealed from the clinical operators until the beginning of implant surgery. the outcome examiners and patients will be kept blinded to the assignment. the required sample size is calculated based on the primary outcome parameter, implant survival rate. a recent study (rossi et al. 2016) compared survival rate of short implants and standard implants (survival rate: 86.7% vs 96.7%). if α=0.05, and 1-β =0.8, a sample size of n=116 per group is required. assuming a drop-out rate of 10%, 125 patients per group will be required. the total required sample size will thus be n=250.

Eligibility criteria:
inclusion criteria: the following inclusion criteria are applied: * age≧18 years, partial edentulism in posterior maxilla for at least three months from tooth loss, * residual bone height range from 6-8mm, * sufficient bone width in edentulous region. exclusion criteria: the patients will be excluded on the basis of: * heavy smoker (\>10 cigarettes per days), * uncontrolled diabetes mellitus or other systemic diseases, * uncontrolled periodontal infection, * insufficient bone quality to achieve implant stability and * previous implant installation or bone grafting at surgical site.

Keywords: short implants sinus floor elevation randomized controlled trial
a study of ly3457263 compared with placebo in participants with type 2 diabetes on a stable dose of semaglutide or tirzepatide

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to measure the change in hemoglobin a1c (hba1c) with ly3457263 compared with placebo in participants with type 2 diabetes who are not at hba1c goal when treated with a stable dose of semaglutide or tirzepatide. participation in the study will last about 9 months.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes * have hba1c ≥7.5% to ≤10.5% at screening * have a body mass index (bmi) of ≥27 kilograms per square meter (kg/m2) at screening * have had a stable body weight for the three months prior to screening * on stable treatment dose of one of the following incretins for at least three months: * injectable semaglutide (1 and 2 milligram (mg)) * injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg) exclusion criteria: * have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma * have a prior or planned surgical treatment for obesity * have any of the following cardiovascular conditions within three months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * have used insulin to control blood glucose within the past year (short-term use allowed) * current use of another oral antihyperglycemic medication (oam) (including but not limited to, dipeptidyl peptidase iv inhibitors (dpp-4i) and meglitinides) may be randomized if the additional oam treatment was discontinued at least 3 months prior to screening * if participant has been on stable doses (for at least three months) of up to three oams (limited to metformin, sodium-glucose cotransporter-2 (sglt2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (tzd), they are permitted to participate in the study * have taken any medications or alternative remedies for weight loss within three months prior to screening

Keywords: obesity overweight
patient retrospective outcomes (pro)

Conditions: Chronic Pain

Summary: this study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.

this study is a retrospective, multi-center, de-identified patient data review. the study will include multiple independent cohorts to evaluate clinical outcomes in different subgroups.

Eligibility criteria:
key inclusion criteria: * previously treated with or eligible for use with boston scientific systems * 18 years of age or older at the start of baseline
ranibizumab and reduced fluence pdt for amd

Conditions: Macular Degeneration

Summary: single agent anti-vegf therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. however, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. the purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.

a randomized, prospective, multicenter trial will compare two groups of patients with subfoveal choroidal neovascularization secondary to amd. one group will receive 0.5 mg. ranibizumab intraocularly initially. this will be repeated monthly for 3 months total and then as needed over the period of one year. the other group will receive reduced fluence-pdt (25 joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. the second group will receive the combination of ranibizumab and rf-pdt as needed over a period of one year. re-treatment will be determined by the individual investigator based on visual acuity, retinal thickness as measured by optical coherence tomography (oct), and fluorescein angiography. visual acuity and oct measurements will be performed by masked examiners.

Eligibility criteria:
inclusion criteria: 1. willingness to sign informed consent. 2. age greater than 50. 3. evidence of macular degeneration in the form of drusen in either eye. 4. visual acuity of 20/25 to 20/800. 5. subfoveal choroidal neovascularization. both occult and classic subtypes will be allowed. if lesion is purely occult there has to be one of the following: 1. recent loss of vision (5 letters on etdrs or doubling of visual angle by snellen) 2. documented enlargement of lesion on fa 3. increase of 50 microns or more in the central subfield on oct 4. new blood 6. total active lesion must be less than 12 disc areas in size. - exclusion criteria: 1. myopia, ocular histoplasmosis, or other retinal pathology that could affect vision 2. previous treatment of the enrolled eye for cnv 3. intraocular surgery within 6 weeks of enrollment 4. geographic atrophy, subretinal fibrosis, or pigment epithelial tear involving the fovea of the eligible eye 5. known hypersensitivity to verteporfin 6. medical condition that would preclude regular follow-up for one year. 7. previous vitrectomy 8. media opacities limiting visual acuity, retinal examination, or retinal imaging. 9. a lesion where \> 50% of the lesion is a pigment epithelial detachment. -

Keywords: anti-vegf therapy photodynamic therapy neovascularization